Tamoxifen ameliorates obstructive nephropathy through Src and the PI3K/Akt/mTOR pathway

被引:23
|
作者
Kim, Chang Seong [1 ]
Kim, In Jin [1 ]
Choi, Joon Seok [1 ]
Bae, Eun Hui [1 ]
Ma, Seong Kwon [1 ]
Kim, Soo Wan [1 ]
机构
[1] Chonnam Natl Univ, Med Sch, Dept Internal Med, Gwangju, South Korea
基金
新加坡国家研究基金会;
关键词
Fibrosis; Kidney; Phosphoinositide; 3-kinase; Src; Tamoxifen; ESTROGEN-RECEPTOR-ALPHA; TUBULOINTERSTITIAL FIBROSIS; KIDNEY INJURY; TGF-BETA/SMAD; THERAPY; INHIBITION; CLOMIPHENE; RALOXIFENE; INDUCTION; TARGET;
D O I
10.1111/boc.201800040
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background information Tubulointerstitial fibrosis is the end-point of chronic kidney diseases. Tamoxifen, a selective oestrogen receptor (ER) modulator, attenuates renal fibrosis, by regulating the transforming growth factor (TGF)-beta/Smad signalling. Src and phosphoinositide 3-kinase (PI3K)/Akt pathways play critical roles in the pathogenesis of renal fibrosis. However, the activation of the non-canonical TGF-beta signalling in renal fibrosis after treatment with tamoxifen remains unclear. Renal fibrosis was induced by unilateral ureteral obstruction (UUO) in rats. Tamoxifen was orally administered after UUO. Additionally, HK-2 cells were treated with tamoxifen in the presence or absence of TGF-beta 1. The selective ER down-regulator ICI and ER-alpha silencing were used to confirm the involvement of ER-alpha on the effect of tamoxifen on TGF-beta 1-stimulated fibrosis in HK-2 cells. Results Tamoxifen treatment ameliorated UUO-induced renal fibrosis as shown by decreased expression of alpha-smooth muscle actin (SMA), fibronectin and connective tissue growth factor (CTGF). The phosphorylation of Src, PI3K, Akt, mammalian target of rapamycin (mTOR) and p70S6K significantly decreased in UUO kidneys from tamoxifen-treated animals. Tamoxifen dose-dependently suppressed the TGF-beta 1-induced expression of alpha-SMA and CTGF, and phosphorylation of Src, PI3K, Akt, mTOR and p70S6K in HK-2 cells. These anti-fibrotic effects were reversed by treatment with ICI and silencing of ER-alpha. Moreover, inhibition of the PI3K/Akt and mTOR/p70S6K pathways was observed in HK-2 cells co-treated with PP1 (a Src kinase inhibitor) and tamoxifen. Conclusions The anti-fibrotic effects of tamoxifen are associated with the suppression of Src kinase function via ER-alpha, followed by inhibition of the PI3K/Akt and mTOR/p70S6K signalling pathways. Significance Our findings suggest that tamoxifen is a novel therapeutic option for the prevention and treatment of renal fibrosis.
引用
收藏
页码:18 / 27
页数:10
相关论文
共 50 条
  • [21] Targeting the mTOR/AKT/PI3K pathway in paediatric malignancies
    Pearson, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S74 - S74
  • [22] AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
    Bhatt, Aadra P.
    Damania, Blossom
    FRONTIERS IN IMMUNOLOGY, 2013, 3
  • [23] Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
    Zhou, Qian
    Lui, Vivian W. Y.
    Yeo, Winnie
    FUTURE ONCOLOGY, 2011, 7 (10) : 1149 - 1167
  • [24] Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
    Dimitrova, V.
    Arcaro, A.
    CURRENT MOLECULAR MEDICINE, 2015, 15 (01) : 82 - 93
  • [25] Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
    Sun, Eun Jin
    Wankell, Miriam
    Palamuthusingam, Pranavan
    McFarlane, Craig
    Hebbard, Lionel
    BIOMEDICINES, 2021, 9 (11)
  • [26] PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
    Lisi, Lucia
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2161 - 2163
  • [27] PI3K/Akt/mTOR pathway as a target for cancer therapy
    Morgensztern, D
    McLeod, HL
    ANTI-CANCER DRUGS, 2005, 16 (08) : 797 - 803
  • [28] PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
    Zhang, Zixuan
    Wang, Mengzhao
    ONCOLOGY LETTERS, 2017, 14 (02) : 1373 - 1378
  • [29] Targeting the PI3K/AKT/mTOR pathway in ovarian cancer
    Musa, Fernanda
    Schneider, Robert
    TRANSLATIONAL CANCER RESEARCH, 2015, 4 (01) : 97 - 106
  • [30] Angelica Sinensis promotes myotube hypertrophy through the PI3K/Akt/mTOR pathway
    Yeh, Tzu-Shao
    Hsu, Cheng-Chen
    Yang, Suh-Ching
    Hsu, Mei-Chich
    Liu, Jen-Fang
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 14